Moderna, Inc. (MRNA)
Is Moderna Stock A Buy As It Faces Off With Pfizer, GSK In The Massive RSV Market?
Is Moderna stock a buy after unveiling promising results for its Pfizer- and GSK-rivaling RSV vaccine? Is MRNA stock a buy now?
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
Moderna (MRNA) reachead $116.07 at the closing of the latest trading day, reflecting a -0.33% change compared to its last close.
3 Healthcare Stocks to Sell in July Before They Crash & Burn
The outlook of many healthcare stocks is quite positive at this point. That's partly because many large investors have shunned the sector, since they believe that it is destined to produce horrible returns as long as interest rates remain elevated.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.
Moderna Receives HHS Grant to Develop a Bird Flu Vaccine
Moderna (MRNA) shares edged higher Tuesday after the biotech firm received a federal grant to develop a vaccine to prevent bird flu in humans.
US awards Moderna $176 million to produce bird flu vaccine
The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said on Tuesday, as concerns rise over a multi-state outbreak of H5N1 virus in dairy cows and infections of three dairy workers since March.
Moderna gets U.S. government funding for bird-flu vaccine development
Moderna Inc.'s efforts to develop a bird-flu vaccine are getting a boost from the U.S. government, the company said Tuesday.
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.
Investors Who Lost Money on Moderna, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - MRNA
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
